ReviewPharmacoEconomics1999
Influenza. The role of burden-of-illness research.
Review in PharmacoEconomics, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 44 citations in OpenAlex.
- Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases.Journal of clinical immunology · 2007Trial
- Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.Journal of virology · 2007Trial
- Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group.PharmacoEconomics · 2000Trial
- Severe and moderate seasonal influenza epidemics among Italian healthcare workers: A comparison of the excess of absenteeism.Influenza and other respiratory viruses · 2021Article
- Increases in absenteeism among health care workers in Hong Kong during influenza epidemics, 2004-2009.BMC infectious diseases · 2015Article
- The impact of influenza-like illness in young children on their parents: a quality of life survey.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2014Article
- Assessment of the intensive countermeasures in the 2009 pandemic influenza in Korea.Osong public health and research perspectives · 2014Article
- The burden of influenza in East and South-East Asia: a review of the English language literature.Influenza and other respiratory viruses · 2008Review
- The impact of influenza on working days lost: a review of the literature.PharmacoEconomics · 2008Review
- Should healthy children be vaccinated against influenza? A consensus report of the Summits of Independent European Vaccination Experts.European journal of pediatrics · 2006Article
- Antiviral agents for influenza: a comparison of cost-effectiveness data.PharmacoEconomics · 2005Review
- Article
- Virological surveillance of influenza-like illness in the community using PCR and serology.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2004Article
- Role of influenza vaccine for healthy children in the US.Paediatric drugs · 2004Review
- A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.PharmacoEconomics · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza is associated with a significant economic burden on both society and the individual, resulting in considerable healthcare costs and loss of productivity, as well as intangible costs such as suffering, grief and social disruption. The incidence and severity of influenza infection depend, at least in part, on the age and health status of the population. For example, the incidence of influenza is relatively high among children and young adults, but serious complications are much more likely to occur among the very young (< 1 year of age) and the elderly (> 65 years of age). School absenteeism tends to peak in the first half of a typical 6- to 8-week influenza epidemic, followed by workplace absenteeism in the latter half as school-aged children pass the infection to family members. Cost-of-illness studies are used by policy-makers to justify budgets and set priorities for prevention programmes, research and other expenditures. On the basis of German Sickness Fund data, recent estimates indicate that the cost of an influenza epidemic in that country is approximately 2 billion Deutschmarks (approximately $US1.4 billion). The bulk of these costs reflects indirect costs associated with lost productivity, a finding also noted in an earlier French cost-of-illness study of influenza. Thus, the main economic burden of influenza falls on infected individuals, their employers and their relatives. Methodology used in cost-of-illness studies can be quite variable. For example, two main approaches are used in measuring indirect costs (human capital and willingness to pay), although there is controversy as to which is the preferred method. Thus, investigators involved in cost-of-illness studies must be explicit regarding study methodology in order to allow for appropriate interpretation of study results by interested parties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.